Weekly update Companies AI-cruiter Recruiting

Asher Biotherapeutics

Founded: 2019

Location: South SF, CA

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: Solid tumors

Drug types: ONC, INF, IMM

Lead product: AB248

Product link: https://asherbio.com/pipeline/

Funding: $108M B Sep 2021; $55M A Mar 2021

Investors: Third Rock, Boxer Capital of Tavistock Group, Invus, Y Combinator, MBC Biolabs

asherbio.com

linkedin.com

job board

Short description:

IL-2 Therapies

Drug notes:

AB821 Clin0 oncology; AB359 Clin0 viral infection; 4 undisclosed programs RD oncology, autoimmune conditions

Long description:

Asher Biotherapeutics is developing immunotherapies for cancer and other diseases. Immunotherapies are a promising strategy for cancer treatment; however, they indiscriminately act on multiple cell types and thus cause side effects. Asher is pioneering cis-targeting immunotherapies that only activate the immune cell types that drive the desired therapeutic effect. Cis-targeting works by engaing two receptors, an immunomodulatory receptor and a specific surface marker, present on the same immune cell to achieve higher selectivity. Asher is identifying drugs using their cis-targeting platform that can be tailored for different immune cells. Asher’s lead molecule, AB248, specifically activates CD8+ effector T cells and is being investigated against multiple solid tumors.

Jobs:

Main

Contact: recruit@workinbiotech.com